Evaluation of the Effect of the "CR500 SINGLE-DOSE GEL" Medical Device in Patients With Knee Osteoarthritis (KOA)

Evaluation of the Effect of the "CR500 SINGLE-DOSE GEL" Medical Device in Patients With Knee Osteoarthritis (KOA): a Post-market Confirmatory Interventional, Single Arm Clinical Investigation

Single arm clinical investigation, post-market confirmatory interventional to assess performance, safety and tolerability of "CR500 SINGLE-DOSE GEL" medical device in patients with knee osteoarthritis (KOA).

Study Overview

• Status: Completed
• Conditions: Knee Osteoarthritis
• Intervention / Treatment: Device: CR 500™ SINGLE-DOSE GEL

Detailed Description

Subjects 26-83 years old will receive CR500 SINGLE-DOSE GEL given for the treatment of osteoarthritis of the knee over a 4-week time period. The primary objective of the study is to evaluate the effect of CR500 SINGLE-DOSE GEL in the treatment of KOA.

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Italy
  • Varese
    • Castellanza, Varese, Italy, 21053
      • Istituto Clinico Mater Domini Casa di Cura Privata - Gruppo Humanitas

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria

1. Male or Female, aged ≥18 years at the time of the signature of ICF (Informed Consent Form).
2. Patients with a diagnosis of primary or secondary KOA affecting only one knee (monolateral KOA) of "mild" (score 1 - 4) or "moderate" (score 5 - 7) severity according to the LKI score.
3. Willing to follow all study procedures, including attending all site visits, tests and examinations.
4. Willing to participate in the study and sign the ICF.

Exclusion criteria

1. Osteoarthritis (OA) in both knees (bilateral KOA).
2. Other - different - clinical conditions of the knee.
3. Infective or inflammatory processes near the area of treatment.
4. Damaged skin in the area of treatment.
5. Ongoing cutaneous allergies.
6. Serious and chronical pathological skin conditions (i.e. rosacea, psoriasis, vitiligo) including diagnosticated cancer with/without ongoing antitumor therapy.
7. Allergy to device components (Sodium hyaluronate; Synthetic Human (SH)-Polypeptide-85; SH-Polypeptide-93; Glycerin; Propylene glycol; Ethylhexylglycerin; Panthenol; Polyethylene Glycol (PEG)-40 hydrogenated castor oil; Sodium hydroxide; Xanthan gum; Phenoxyethanol; Benzoic Acid; Carbomer; Dehydroacetic Acid; Disodium EDTA).
8. Any other systemic or local therapy for the treatment of KOA.
9. Any other systemic or local therapy (e.g. NSAIDs, corticosteroids) for the treatment of other inflammatory diseases (e.g. dermatitis, acute or chronic bronchitis, gastroenteritis, etc.) or painful states (e.g. headache, dental abscess, etc.) that may interfere with the clinical course of KOA under treatment with the medical device CR500.
10. Immune system illnesses.
11. Uncontrolled systemic diseases.
12. Known drug and/or alcohol abuse.
13. Mental incapacity that precludes adequate understanding or cooperation.
14. Participation in another investigational study.
15. Pregnancy* or breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: CR500 single-dose gel; Interventional study on CR500 1.5 mL will be topically administered twice a week for four weeks	Device: CR 500™ SINGLE-DOSE GEL; CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OA evaluation, measured by Lequesne Knee Index (LKI)	The primary efficacy endpoint of the study will be the evaluation of the clinical performance of the CR 500™, used as intended in patients affected by KOA, in variation of symptoms related to the physiological degeneration of cartilage typical of osteoarthritic processes, in terms of difference in LKI score between the end study visit and baseline visit. Lequesne Knee Index Score: minimum index score: 0 maximum index score: 24 0 means none OA >= means extremely severe OA	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lequesne Knee Index (LKI) Score	To evaluate the clinical performance of the CR 500™ across the study by Lequesne Knee Index (LKI) score. Lequesne Knee Index Score: minimum index score: 0 maximum index score: 24 0 means none OA >= means extremely severe OA	4 weeks
Lequesne Knee Index (LKI) Subscore	To evaluate the clinical performance of the CR 500™ by each Lequesne Knee Index (LKI) subscore Lequesne Knee Index Score: minimum index score: 0 maximum index score: 24 0 means none OA >= means extremely severe OA	4 weeks
Symptoms Variation in terms of Lequesne Knee Index (LKI) score	To evaluate the clinical performance of the CR 500™ in the attenuation of symptoms in patients affected by KOA stratified by KOA severity as assessed by Lequesne Knee Index (LKI) score	4 weeks
Cluster of Subjective Symptoms evaluated by Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire	To evaluate the different dimensions of the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire Koos converted into a 0-100 Score 0 means worst level of OA 100 means best level of OA Subscores: Pain, Symptoms, Sports, Quality of Life, Activities of Daily Living	4 weeks
Number of participants with treatment-related adverse event as assessed by a questionnaire.	To evaluate the side effects of the product CR 500™ through a the completion of a specific questionnaire by the patient.	4 weeks
Product tolerability and patient satisfaction as assessed by a questionnaire using a five-points Likert scale	To evaluate the tolerability and patient satisfaction of the CR 500™ through a the completion of a specific questionnaire by the patient, the five-points Likert scale in which 1 means Strongly disagree with the assertion and 5 means Strongly agree	4 weeks
Evaluation of the status of the cartilage degradation by quantification of neoepitope of type II collagen (C2C)	Evaluation of the status of the cartilage degradation by quantification of neoepitope of type II collagen in synovial fluid by ELISA (ng/mL)	4 weeks
Evaluation of the status of the cartilage degradation by quantification of C-terminal telopeptide of type II collagen (CTX-II)	Evaluation of the status of the cartilage degradation by quantification of C-terminal telopeptide of type II collagen quantification (CTX-II) in synovial fluid by ELISA (pg/mL)	4 weeks
Evaluation of the status of the cartilage by quantification of type II collagen propeptide (CPII) quantification	Evaluation of the status of the cartilage by quantification of type II collagen propeptide (CPII) in synovial fluid by ELISA (ng/mL)	4 weeks
Evaluation of the status of the cartilage by quantification of hyaluronic acid (HA) quantification	Evaluation of the status of the cartilage by quantification of hyaluronic acid (HA) in synovial fluid by ELISA (mg/mL)	4 weeks
Evaluation of the inflammatory status of the knee joint by quantification of tumour necrosis factor (TNF) quantification	Evaluation of the status of the cartilage by quantification of tumour necrosis factor (TNF) in synovial fluid by ELISA (pg/mL)	4 weeks
Evaluation of the macrophages infiltration in the knee joint by quantification of Cluster of Differentiation 206 (CD206)	Evaluation of the macrophages infiltration in the knee joint by quantification of Cluster of Differentiation 206 (CD206) by Real Time Polymerase Chain Reaction (PCR)	4 weeks
Evaluation of the macrophages infiltration in the knee joint by quantification of Cluster of Differentiation 11c (CD11c)	Evaluation of the macrophages infiltration in the knee joint by quantification of Cluster of Differentiation 11c (CD11c) by Real Time PCR	4 weeks

Collaborators and Investigators

• Sponsor: Contrad Swiss SA

Study record dates

Study Major Dates

• Study Start (Actual): February 17, 2021
• Primary Completion (Actual): May 18, 2021
• Study Completion (Actual): May 18, 2021

Study Registration Dates

• First Submitted: November 16, 2022
• First Submitted That Met QC Criteria: December 13, 2022
• First Posted (Estimate): December 22, 2022

Study Record Updates

• Last Update Posted (Estimate): December 22, 2022
• Last Update Submitted That Met QC Criteria: December 13, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: Hyaluronic acid; Peptides; Biochemical markers; Knee osteoarthritis;; Synovial fluid; Algofunctional scores; Macrophages infiltration
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: CTD-SW CR500-KOA 2020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No